CD19CAR-28-zeta T cells

N/A

Report date: 2025/03/19 20:00:56

Base Information

Drug NameCD19CAR-28-zeta T cells
Drug Alias Nameanti-CD19 CAR T-cell therapy (Baylor College of Medicine)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionB-lymphocyte antigen CD19 modulators
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsMultiple MyelomaLymphoma, Non-HodgkinLymphoma +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesBaylor College Of Medicine
China Registration ClassN/A

Develop Information

Active CompaniesBaylor College Of Medicine
Inactive CompaniesN/A
Active IndicationsMultiple MyelomaLymphoma, Non-HodgkinLymphoma +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A